Answers are grounded in this paper and cite their sources.
Case report shows stem cell boost improves hematotoxicity in a patient after CAR T-cell therapy, indicating new treatment potential.
Prolonged and refractory hematotoxicity is a severe complication of anti‐BCMA CAR‐T cell therapy, associated with substantial morbidity. When conventional supportive measures (transfusions and hematopoietic growth factors) fail, alternative strategies are urgently needed. We report the case of a 55‐year‐old man who developed persistent cytopenias after idecabtagene vicleucel. Reinfusion of cryopreserved autologous stem cells (stem cell boost), administered without conditioning chemotherapy, resulted in rapid and complete hematopoietic recovery after 14 days. This case highlights the potential of stem cell boost as a salvage approach for prolonged post‐CAR‐T hematotoxicity and underscores the need for prospective multicenter studies to standardize indications, timing, and procedures for this intervention.
No takes yet. Share an insight, caveat, or question.
Loukhnati et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: